Our story began in 1979 when Dr Rolland-Yves Mauvernay, convinced that many useful therapeutic products were abandoned before reaching their full potential, decided to found the Swiss-based Debiopharm Group.
Dr Rolland-Yves Mauvernay was known as “Monsieur Molecule”. Before founding Debiopharm, he established RIOM Laboratories in 1953 (Auvergne, France) and purchased several pharmaceutical companies and various molecules. After selling RIOM in 1973, he could have retired from the pharma industry, but his passion drove him forward. In the same year, Prof Andrew Schally (Nobel Prize in Physiology or Medicine in 1977) performed the first synthesis of GnRH agonist Triptorelin. Dr Mauvernay immediately saw value in the compound when others didn’t. A new chapter began with their collaboration and Dr Mauvernay founded Debiopharm.
Success was not long in coming with the development of two standard of care treatments: Triptorelin to fight prostate cancer and Oxaliplatin in the treatment of colorectal cancer. Since their respective commercialization, both products have been made available to patients worldwide in these and other indications.
Having started with only two people (Dr Mauvernay & his secretary), Debiopharm is now a group of five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management. At the heart of the drug development process, the group in-licenses and develops promising compounds such as small molecules or biologics, generally in early-stage development, in order to transform them into valuable drugs for the patients. Debiopharm also acquires and takes options on compounds. Its main therapeutic areas are oncology and infectious diseases.
The Group is now headed up by Mr Thierry Mauvernay, driven by the same passion as his father. He is fully committed to the group’s current activities and planning the future to ensure long-term continuity.
Most importantly, relationships between people and the quality of Debiopharm Group's staff have made the greatest contribution to pave the way to the group's success. Today more than 420 employees make the strength of Debiopharm Group.